Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
April 16, 2024 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and...
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
April 16, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
April 16, 2024 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024
April 09, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- The results of a study in collaboration with the Food and Drug Administration (FDA), the American Academy of Ophthalmology (Academy), and Verana...
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
April 05, 2024 07:02 ET
|
Ocugen
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen,...
Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind
April 04, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today...
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
April 02, 2024 08:00 ET
|
Ocugen
Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical...